Concepedia
Statistics
Publications
48
Citations
2K
H-Index
24
Active since
1984
Affiliations
Johnson & Johnson (United States)(Current)
Springhouse
Einstein Medical Center Philadelphia
Robert Wood Johnson University Hospital
South College
Lawrence de Garavilla is an author at Johnson & Johnson (United States) specializing in medicine, pharmacology, and pharmacotherapy.
Top concepts
MedicinePharmacologyPharmacotherapyDrug DiscoveryPhysiologyBiochemistryVascular BiologyNatural SciencesMedicinal ChemistryCardiovascular Disease
Publications per year
1984–2018
Cardiovascular Responses Mediated by Protease-Activated Receptor-2 (PAR-2) and Thrombin Receptor (PAR-1) are Distinguished in Mice Deficient in PAR-2 or PAR-1
Bruce P. Damiano, Wai Cheung, Rosemary J. Santulli et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 182 citations
Agonists of proteinase‐activated receptor 1 induce plasma extravasation by a neurogenic mechanism
Lawrence de Garavilla, Nathalie Vergnolle, Steven H. Young et al. · British Journal of Pharmacology · 2001 · 140 citations · Full text
Administration of a Potent Antagonist of Protease-Activated Receptor-1 (PAR-1) Attenuates Vascular Restenosis Following Balloon Angioplasty in Rats
Patricia Andrade‐Gordon, Claudia K. Derian, Bruce E. Maryanoff et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 112 citations
Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney
Andrew Y. Zhang, Yafei Chen, David X. Zhang et al. · American Journal of Physiology-Renal Physiology · 2003 · 102 citations
A Novel, Potent Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase
Lawrence de Garavilla, Michael N. Greco, N. Sukumar et al. · Journal of Biological Chemistry · 2005 · 92 citations · Full text
Potent Dual Inhibitor, Molecular Biology, Serine Proteases +17
1–5 of 48